Welcome to our dedicated page for Eikon Therapeutics news (Ticker: EIKN), a resource for investors and traders seeking the latest updates and insights on Eikon Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Eikon Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Eikon Therapeutics's position in the market.
Eikon Therapeutics (Nasdaq: EIKN) reported corporate and clinical updates on March 30, 2026, including a closed upsized IPO raising $381.2 million and a cash, cash equivalents and marketable securities balance of $336.0 million as of December 31, 2025. The company expects cash to fund operations into the second half of 2027.
Clinical progress: completed enrollment in the TeLuRide-005 Phase 2 trial of EIK1001 with data expected in 2H 2026; EIK1003 and EIK1004 Phase 1/2 programs advancing with a cohort start anticipated in 2H 2026; EIK1005 healthy volunteer study completed and patient trial underway. Financials show year-over-year increases in R&D and G&A and a 2025 net loss of $333.6 million.
Eikon Therapeutics (Nasdaq:EIKN) priced an upsized initial public offering of 21,177,600 shares at $18.00 per share, with gross proceeds expected to be approximately $381 million before fees. The underwriters have a 30-day option for an additional 3,176,640 shares.
Shares are expected to begin trading on the Nasdaq Global Select Market on February 5, 2026, with the offering scheduled to close on or about February 6, 2026, subject to customary closing conditions.